Costs of multiple sclerosis in Serbia

IF 1.8 4区医学 Q3 CLINICAL NEUROLOGY

Journal of Clinical Neuroscience Pub Date : 2025-07-02 DOI:10.1016/j.jocn.2025.111437

Jovana Ivanovic , Jovan Mihajlovic , Marko Andabaka , Vanja Jovicevic , Gorica Maric , Aleksa Jovanovic , Sarlota Mesaros , Tatjana Pekmezovic , Jelena Drulovic

{"title":"Costs of multiple sclerosis in Serbia","authors":"Jovana Ivanovic , Jovan Mihajlovic , Marko Andabaka , Vanja Jovicevic , Gorica Maric , Aleksa Jovanovic , Sarlota Mesaros , Tatjana Pekmezovic , Jelena Drulovic","doi":"10.1016/j.jocn.2025.111437","DOIUrl":null,"url":null,"abstract":"<div><div>The value of economic studies for decision making in health care has been widely recognized. The aim of this study was to estimate the annual costs of multiple sclerosis (MS) in Serbia. This is a cross-sectional study in which data on resource consumption and work capacity, and health-related quality of life (HRQoL) in MS patients, at the Clinic of Neurology, UCCS in Belgrade, were collected. A total of 356 patients (mean age, 42 years), out of which 271 treated with interferon beta agents, and the remaining 85 untreated, participated in this study. Ninety eight percent were below retirement age, and out of these, 54 % were employed. Employment decreased rapidly with advancing disability; 66 % of patients with Expanded Disability Status Scale (EDSS) 0–3.5 were employed, 31 % of those with EDSS 4.0–6.5, and 11 % with EDSS 7.0 and above. All HRQoL domains included in the EQ-5D displayed disturbances for a large number of patients: pain/discomfort for 67 %, usual activities 61 %, mobility 64 %, anxiety and depression 72 % and self-care 21 %. Total annual costs for patients treated with DMTs were 8,860 EUR and for the untreated 9,519 EUR, increasing significantly with worsening disability. This study describes the burden of MS in Serbian patients and provides data that are important for development of health policies.</div></div>","PeriodicalId":15487,"journal":{"name":"Journal of Clinical Neuroscience","volume":"139 ","pages":"Article 111437"},"PeriodicalIF":1.8000,"publicationDate":"2025-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical Neuroscience","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0967586825004102","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

The value of economic studies for decision making in health care has been widely recognized. The aim of this study was to estimate the annual costs of multiple sclerosis (MS) in Serbia. This is a cross-sectional study in which data on resource consumption and work capacity, and health-related quality of life (HRQoL) in MS patients, at the Clinic of Neurology, UCCS in Belgrade, were collected. A total of 356 patients (mean age, 42 years), out of which 271 treated with interferon beta agents, and the remaining 85 untreated, participated in this study. Ninety eight percent were below retirement age, and out of these, 54 % were employed. Employment decreased rapidly with advancing disability; 66 % of patients with Expanded Disability Status Scale (EDSS) 0–3.5 were employed, 31 % of those with EDSS 4.0–6.5, and 11 % with EDSS 7.0 and above. All HRQoL domains included in the EQ-5D displayed disturbances for a large number of patients: pain/discomfort for 67 %, usual activities 61 %, mobility 64 %, anxiety and depression 72 % and self-care 21 %. Total annual costs for patients treated with DMTs were 8,860 EUR and for the untreated 9,519 EUR, increasing significantly with worsening disability. This study describes the burden of MS in Serbian patients and provides data that are important for development of health policies.

查看原文本刊更多论文

塞尔维亚多发性硬化症的费用

经济研究对医疗保健决策的价值已得到广泛认可。本研究的目的是估计塞尔维亚多发性硬化症（MS）的年度成本。这是一项横断面研究，收集了贝尔格莱德UCCS神经病学诊所MS患者的资源消耗、工作能力和健康相关生活质量（HRQoL）的数据。共有356例患者（平均年龄42岁）参加了这项研究，其中271例接受干扰素治疗，其余85例未接受治疗。98%的人在退休年龄以下，其中54%的人有工作。随着残疾程度的加深，就业迅速下降；扩展残疾状态量表（EDSS） 0-3.5分占66%，EDSS 4.0-6.5分占31%，EDSS 7.0及以上分占11%。EQ-5D中包含的所有HRQoL域在大量患者中显示出障碍：67%的患者疼痛/不适，61%的患者通常活动，64%的患者活动能力，72%的患者焦虑和抑郁，21%的患者自我护理。接受dmt治疗的患者的年总费用为8,860欧元，未接受治疗的患者为9,519欧元，随着残疾的恶化而显著增加。本研究描述了塞尔维亚患者的多发性硬化症负担，并为卫生政策的制定提供了重要的数据。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Clinical Neuroscience 医学-临床神经学

CiteScore

4.50

自引率

0.00%

发文量

402

审稿时长

40 days

期刊介绍： This International journal, Journal of Clinical Neuroscience, publishes articles on clinical neurosurgery and neurology and the related neurosciences such as neuro-pathology, neuro-radiology, neuro-ophthalmology and neuro-physiology. The journal has a broad International perspective, and emphasises the advances occurring in Asia, the Pacific Rim region, Europe and North America. The Journal acts as a focus for publication of major clinical and laboratory research, as well as publishing solicited manuscripts on specific subjects from experts, case reports and other information of interest to clinicians working in the clinical neurosciences.